Home > Insider Trading > Filing (0001415889-25-020087)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Enliven Therapeutics Inc.	ELVN	Pharmaceutical Preparations (2834)	811523849

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1967168	Samuel Kintz	C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301	President And Ceo	No	No	No	No

Transaction Summary

Sold:	12,500 shares	Avg. Price: $22.52	Total Value: $281,517.86
Number of Shares After Transactions:	940,392 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-07-17	4,150	$21.58	948,742	No	4	S	Indirect	See footnote
Common Stock	Disposition	2025-07-17	4,687	$22.69	944,055	No	4	S	Indirect	See footnote
Common Stock	Disposition	2025-07-17	3,663	$23.37	940,392	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
This transaction was executed in multiple trades at prices ranging from $21.26 to $22.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
This transaction was executed in multiple trades at prices ranging from $22.28 to $23.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $23.285 to $23.595. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.